Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer

Medicine and Dentistry

• Bladder 10%
• Bladder Cancer 20%
• Bladder Carcinoma 10%
• Cancer Model 10%
• Carcinoma in Situ 10%
• Clinical Support 10%
• Cytokine 10%
• Cytotoxicity 10%
• Cytotoxicity Assay 10%
• Effector Cell 20%
• Granzyme B 10%
• In Vitro 20%
• Mycobacterium bovis 10%
• Mycobacterium Bovis BCG 70%
• Natural Killer Cell 10%
• Neoplasm 30%
• Non Muscle Invasive Bladder Cancer 40%
• Obstetric Delivery 10%
• Patient 30%
• Recurrent Disease 10%
• Specific Tumor 10%
• T Cell 10%
• Therapeutic Procedure 50%
• Tissue Injury 10%
• Tissues 10%
• Toxicity 10%
• Tuberculosis 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Bacilli 100%
• Bladder Cancer 20%
• Bladder Carcinoma 10%
• Cancer Model 10%
• Carcinoma in Situ 10%
• Cytokine 10%
• Cytotoxicity 10%
• Granzyme B 10%
• Mouse 20%
• Mycobacterium bovis 10%
• Mycobacterium Bovis BCG 70%
• Neoplasm 30%
• Non Muscle Invasive Bladder Cancer 40%
• Recurrent Disease 10%
• Tissue Injury 10%
• Tolerability 20%
• Toxicity 10%
• Tuberculosis 10%

Biochemistry, Genetics and Molecular Biology

• Bacilli 100%
• CD8 10%
• CD8+ Cell 10%
• Cytokine 10%
• Cytotoxicity 10%
• Cytotoxicity Assay 10%
• Granzyme B 10%
• Mouse 20%
• Mycobacterium bovis 10%
• Mycobacterium Bovis BCG 70%
• Mycobacterium Tuberculosis 10%
• Natural Killer Cell 10%
• Syngenic 10%